Neurocrine Biosciences
NBIX
NBIX
223 hedge funds and large institutions have $5.88B invested in Neurocrine Biosciences in 2017 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 98 increasing their positions, 51 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
1.1% more ownership
Funds ownership: 107.69% → 108.79% (+1.1%)
1% more funds holding
Funds holding: 221 → 223 (+2)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
Holders
223
Holding in Top 10
7
Calls
$37.3M
Puts
$23.2M
Top Buyers
| 1 | +$74.4M | |
| 2 | +$40.8M | |
| 3 | +$36.9M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$36.2M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$12.6M |
Top Sellers
| 1 | -$62.4M | |
| 2 | -$34.5M | |
| 3 | -$28.4M | |
| 4 |
Bank of New York Mellon
New York
|
-$21.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19M |